NeuroVigil and Roche collaborate to speed up drug development for CNS disorders

Oct 30 2009

Today, leading California Neurotechnology company NeuroVigil and Swiss Pharma giant Roche announced an agreement regarding a major innovation in collecting and analyzing data from clinical trials.

NeuroVigil will provide Roche with its iBrain devices and accompanying software analysis services to help speed up Roche’s drug development for various CNS disorders. NeuroVigil’s advanced portable, noninvasive iBrain^TM devices will be used to monitor neural activity in outpatient clinical trials. NeuroVigil will analyze the resulting data on a patient-by-patient basis using the NeuroVigil proprietary software algorithms and brain derived biomarker libraries to further characterize the compounds from Roche. These services will enable Roche to detect subtle individual changes in brain activity at very low drug dosages, often before the onset of cognitive symptoms and adverse effects.

“NeuroVigil is delighted to join forces with Roche, the world’s largest diagnostics company, and advance on a path of innovation and discovery, likely to accelerate the pace at which we can make early and significant contributions to the lives of many patients suffering from, or about to develop, a major neuropathological condition,” observed Dr. Philip Low, Founder, Chairman and CEO of NeuroVigil.